Table 1

Baseline characteristics of patients with rheumatoid arthritis (RA) studied

Given TNF-α-blocking therapy

Controlsa


Characteristic

All patients N = 289

Patients with dermatological events N = 72

N = 289


Male sex, no. (%)

89 (31)

20 (28)

110 (38)

Age (yr) at diagnosis, mean (SD)

44.5 (14.7)

43.4 (12.7)

54.6 (14.1)**

RF-positive, no. (%)

249 (87)

68 (94)

205 (71)*

Disease duration (yr) at baseline, median (range)

9.2 (0.1–44.9)

10.3 (0.3–44.9)

6.2 (0.0–12.6)**

DAS28 at baseline, mean (SD)

5.9 (1.1)

6.1 (1.1)

3.6 (1.4)**

ANA-positive at baseline, no. (%)b

112 (50)

33 (49)

118 (41)

Prior DMARDs, median (range)

4 (1–10)

5 (2–8)

1 (0–6)**

Prednisolone at baseline, no. (%)

112 (39)

34 (47)

21 (7)**


aNot given TNF-α-blocking therapy. bANA at start was present in respectively 261 and 67 patients on TNF-α-blocking therapy. *P < 0.001, **P < 0.0001, compared with RA patients on TNF-α-blocking therapy; P < 0.001 compared with RA patients on TNF-α-blocking therapy who experienced no dermatological events. ANA, antinuclear antibody; DAS28, disease activity score based on 28 joints; DMARD, disease-modifying antirheumatic drug; RF, rheumatoid factor; SD, standard deviation; TNF, tumor necrosis factor.

Flendrie et al. Arthritis Research & Therapy 2005 7:R666-R676   doi:10.1186/ar1724

Open Data